Peter Thiel, PayPal co-founder, and Facebook’s very first investor, HAS INVESTED OVER US$11.9 MILLION IN PSYCHEDELICS MARKET
Sector front-running investors like Facebook’s first investor and PayPal’s co-founder Peter Thiel are jumping headfirst into the healthcare market. Core One Labs provides an exciting entrant on the ground floor of the psychedelics industry. Psychedelics are currently at the for front of cutting-edge addiction therapy and depression treatments and have just been legalized for physician prescribed medical use in Canada!
The market in psychedelic healthcare is on a trajectory to surpass $11 BILLION by 2029, growing from USD 4.87 Billion in 2022 (1).
.png)
First to Market, Revolutionary Technology!
The Company recently announced its industry-changing and first-to-market patent-pending biosynthetic psilocybin production system technology, positioning Core One at the forefront of psychedelic companies in the race to innovate mental health and addiction treatments and lead the next frontier in mental health. This ground breaking technology has the potential to produce psilocybin at 1/15th of current market price (2).
Mental health disorders are on the rise in every country of the world and costs to the global economy could reach $16 trillion by 2030 (The Lancet Commission on global mental health and sustainable development, 2018).
Under the leadership of Executive Chairman, Dr. Hancock, Order of Canada inductee, Core One Labs has optimized DNA sequences that can produce biosynthesized psilocybin, that is stereochemically sound (ie. it has the same molecular structure as natural occurring psilocybin found in ‘magic’ mushrooms), can be produced at scale, and can be formulated to ensure a consistent concentration of the effective psychoactive compounds used for exact dosing and prescription.
Dr. Robert Hancock
Executive Chairman
Dr. Robert Hancock is a world-renowned microbiologist, researcher and professor at the University of British Columbia. He has published more than 800 papers and reviews, is an ISI highly cited author in Microbiology with more than 113,000 citations.
Dr. Hancock’s work has resulted in 72 awarded scientific patents, and earned him numerous awards and honours including, the Prix Galien Award (Highest Award for Canadian Pharmaceutical Research and Innovation), the Killam Prize (Canada Council’s prize for Health Research), Michael Smith CIHR Researcher of the Year Award, the ICAAC Aventis Antimicrobial Research Award (Leading award worldwide for antimicrobial research) and an induction as an Officer of the Order of Canada (Canada’s second-highest honour).
With cost estimates at 1/15th of the cost other psychedelic companies’ production costs, Core One’s optimized biosynthetic psilocybin is a game-changer for the psychedelic health care market, and mental health and addictions research. Core One’s biosynthetic psilocybin can replace currently cost-prohibitive psychedelic drugs on the market and avail clinicians and physicians to cost effective, and chemically sound alternatives for their research and treatment efforts.
…and this is just the beginning! Core One’s proprietary production system has the potential to advance the Company’s other psychedelic compounds currently in the production pipeline, and provide a catalogue of psychedelic drugs in the near future along with treatment protocols to be examined at Company’s chain of clinics.
There is no time like the present! With Canada giving psychedelics the ‘green light’ for medical use and Core One Labs achieving a revolutionary status with its proprietary breakthrough, market predictors can see the benefit of moving quickly on this ground floor opportunity, before the company realizes its full potential and value.
The last time Core One announced a major breakthrough, in early February of 2021, investors sent COOL.CN stock to new highs and the Company is now looking to repeat its history of success.
In the Media
“THE POTENTIAL OF PSYCHEDELICS FAR EXCEEDS THE POTENTIAL OF CANNABIS,”stated Kevin O’Leary, Shark Tank co-host and chairman of O’Shares ETFs (CNBC’s Healthy Returns Summit in May ’21)
Will this be you?
While this industry is still in its early stages, the promising potential of psychedelic medicines and pharmaceutical grade products is attracting savvy investors eager to capitalize on the emerging investment opportunities psychedelic stocks present.
